吉林省集安益盛药业股份有限公司 （以下无正文） （本页无正文，为《独立董事关于控股股东及其他关联方占用公司资金和公司对 外担保情况的专项说明和独立意见》之签署页） 独立董事： 独立董事关于控股股东及其他关联方占用公司资金 和公司对外担保情况的专项说明和独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》、《上市公司自律 监管指引第1号—主板上市公司规范运作》、《深圳证券交易所股票上市规则》 和《吉林省集安益盛药业股份有限公司章程》等有关规定，作为吉林省集安益盛 药业股份有限公司（以下简称"公司"）的独立董事，我们本着对公司、全体股 东及投资者负责的态度，按照实事求是的原则，对公司2023年半年度控股股东及 其他关联方占用公司资金及公司对外担保情况进行了认真的检查和落实，并作如 下专项说明及独立意见： 1、报告期内公司不存在控股股东及其他关联方占用公司资金情况，也不存 在以前期间发生并延续到报告期的控股股东及其他关联方占用公司资金的情况。 2、报告期内公司不存在为股东、实际控制人及其关联方、任何非法人单位 或个人提供担保的情况，也不存在以前期间发生并延续到报告期的对外担保事项。 公司当期和累计对外担保金 ...

吉林省集安益盛药业股份有限公司（以下称"公司"）第八届董事会第八次 会议通知以当面送达、电话、邮件的方式于2023年8月17日向各董事发出，会议 于2023年8月24日以现场会议的方式在公司四楼会议室召开。会议应参加审议董 事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《2023年半年 度报告及其摘要》。 《2023年半年度报告全文》详见公司指定信息披露网站巨潮资讯网 (www.cninfo.com.cn)。 《2023年半年度报告摘要》详见公司指定的信息披露媒体巨潮资讯网 （www.cninfo.com.cn）及《中国证券报》、《上海证券报》、《证券时报》。 特此公告。 吉林省集安益盛药业股份有限公司董事会 证券代码：002566 证券简称：益盛药业 公告编号：2023-026 吉林省集安益盛药业股份有限公司 第八届董事会第八次会议决议公告 二〇二三年八月二十四日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大 ...

上市公司2023年6月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：吉林省集安益盛药业股份有限公司 金额单位：人民币元 | 非经营性资金占 用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2023年初占用 资金余额 | 2023年1-6月往来累计发 生金额（不含利息） | 2023年1-6月往来 资金的利息（如有 | 2023年度偿还 累计发生额 | 2023年6月末占 用资金余额 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | ） | | | | | | 现大股东及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | | | | | | | | | | | | | | | | 非经营性占用 | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前大股东及其附 | | | | | | | | | | 非经营性占用 | ...

特此公告。 吉林省集安益盛药业股份有限公司监事会 二〇二三年八月二十四日 吉林省集安益盛药业股份有限公司（以下称"公司"）第八届监事会第八次 会议通知以当面送达、电话的方式于2023年8月17日向各监事发出，会议于2023 年8月24日以现场会议方式在公司四楼会议室召开。会议应当出席的监事3人，实 际出席的监事3人。本次会议的召集、召开程序符合《公司法》等有关法律、法 规及《公司章程》的规定。会议由监事会主席于晓静女士主持，审议并通过了如 下议案： 会议以3票同意、0票反对、0票弃权的表决结果，审议通过了《2023年半年 度报告及其摘要》。 经审核，监事会认为董事会编制和审核公司2023年半年度报告的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 证券代码：002566 证券简称：益盛药业 公告编号：2023-027 吉林省集安益盛药业股份有限公司 第八届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

证券代码：002566 证券简称：益盛药业 公告编号：2023-025 吉林省集安益盛药业股份有限公司 关于控股子公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）控股子公司益盛汉参化 妆品有限公司因自身业务需要，对经营范围进行了变更，并于近日完成了工商变更 登记手续，取得了由集安市市场监督管理局换发的营业执照。具体变更事项如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 经营范围 | 许可项目：化妆品生产；食品销 | 许可项目：化妆品生产；食品销 | | | 售；保健用品（非食品）销售； | 售；保健用品（非食品）销售； | | | 酒类经营；生活美容服务；互联 | 酒类经营；生活美容服务；互联 | | | 网信息服务；道路货物运输（不 | 网信息服务；道路货物运输（不 | | | 含危险货物）。（依法须经批准 | 含危险货物）；第三类医疗器械 | | | 的项目，经相关部门批准后方可 | 经营；用于传染病防治的消毒产 | | | 开展经营 ...

证券代码： 002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 22 日 (周一) 下午 14:00~16:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、总经理薛晓民 | | 员姓名 | 2、董事会秘书李铁军 | | | 3、财务总监毕建涛 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、近几年公司营收变化总是不大，利润也不高，是什么原 | | | 因？公司业务无法推进吗？ | | | 近三年由于疫 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 证券代码：002566 证券简称：益盛药业 公告编号：2023-013 吉林省集安益盛药业股份有限公司 关于参加网上集体业绩说明会的公告 （问题征集专题页面二维码，扫码自动匹配移动端） 特此公告。 吉林省集安益盛药业股份有限公司董事会 二〇二三年五月十二日 为进一步加强与投资者的互动交流，吉林省集安益盛药业股份有限公司（以 下简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有 限公司共同举办的"2023年吉林辖区上市公司网上集体业绩说明会"，现将有关 事项公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与 公司业绩说明会,时间为2023年5月22日（星期一）14:00至16:00。 届时公司总经理薛晓民先生、董事会秘书李铁军先生、财务总监毕建涛先生 将通过网络在线问答互动的形式，与投资者就2022年经营业绩等投资者关注的问 题进行交流。期间，公司高管将全程在线，实时回答投资者的提 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 250,973,766.69, representing an increase of 11.28% compared to CNY 225,540,617.25 in the same period last year[4] - Net profit attributable to shareholders was CNY 28,702,562.15, up by 5.41% from CNY 27,229,639.30 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.0867, reflecting a growth of 5.35% from CNY 0.0823[4] - Operating profit increased to ¥39,719,516.33, reflecting a growth of 18.3% from ¥33,666,091.21 in the last period[16] - Net profit for the current period was ¥31,391,147.16, a rise of 7.4% compared to ¥29,228,860.26 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 106.11%, reaching CNY 80,326,480.85 compared to CNY 38,973,399.49 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥80,326,480.85, significantly higher than ¥38,973,399.49 in the previous period[20] - Cash and cash equivalents at the end of the period totaled ¥435,152,569.03, compared to ¥200,989,827.14 at the end of the previous period[21] - The company's cash and cash equivalents increased to RMB 435,152,569.03 from RMB 343,263,877.76, representing a growth of approximately 27%[13] - The company reported a net increase in cash and cash equivalents of ¥91,888,691.27, contrasting with a decrease of ¥18,705,189.26 in the prior period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,012,881,593.88, a 1.56% increase from CNY 2,966,606,675.95 at the end of the previous year[4] - Current assets reached RMB 2,359,212,920.22, up from RMB 2,302,612,638.12, indicating an increase of about 2.5%[13] - Total liabilities stood at RMB 732,062,391.35, compared to RMB 717,178,620.58 at the beginning of the year, showing a slight increase of about 2.1%[14] - The company's total equity rose to RMB 2,280,819,202.53 from RMB 2,249,428,055.37, reflecting an increase of approximately 1.4%[14] - Short-term borrowings increased to RMB 470,447,708.34 from RMB 430,427,013.89, marking an increase of about 9.3%[14] Operating Costs and Expenses - Operating costs rose by 31.77% to CNY 70,618,510.44, primarily due to increased revenue[5] - Total operating costs amounted to ¥221,979,729.88, up 11.1% from ¥199,827,029.66 in the prior period[16] - Financial expenses decreased significantly by 71.27%, totaling CNY 749,875.57, attributed to increased interest income from agreement deposits[5] - Research and development expenses rose to ¥5,323,126.61, compared to ¥4,342,941.68 in the previous period, indicating a focus on innovation[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,625, with the largest shareholder holding 39.08% of the shares[8] - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[10] - The company aims to resolve the shareholding proxy issue in the shortest time possible while considering the impact on the secondary market[10] Regulatory Compliance - The company is focused on ensuring the accuracy and completeness of its financial disclosures following regulatory requirements[10] - The company has not undergone an audit for the first quarter report[22] Government Subsidies and Fair Value Gains - The company received government subsidies amounting to CNY 11,018,215.10, which are closely related to its normal business operations[5] - The company reported a 49.42% increase in fair value gains, amounting to CNY 1,160,582.03, influenced by changes in the value of financial products[5] - The company reported a decrease in inventory from RMB 1,603,100,929.50 to RMB 1,592,167,434.20, a reduction of approximately 0.7%[13]

证券代码：002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司投资者关系活动记录表 编号：2023-001 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □√ 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人员 姓名 通过"全景•路演天下"（http://ir.p5w.net）参与 2022 年度业绩网上说明会的广大投资者 时间 2023 年 4 月 26 日 地点 全景•路演天下（http://ir.p5w.net） 上市公司接待人员姓 名 总经理 薛晓民 董事会秘书 李铁军 副总经理兼财务总监 毕建涛 独立董事 李明 投资者关系活动主要 内容介绍 公司于 2023 年 4 月 26 日（星期三）下午 15:00-17:00 在 全景网举行 2022 年度业绩网上说明会，本次年度业绩说 明会采用网络远程的方式举行，说明会问答环节主要内容 详见附件。 附件清单（如有） 公司 2022 年度业绩网上说明会问题列表 日期 2023 年 4 月 26 日 2、怎么不生产人参口服液，人参糖片，等消费次数多的产品 答: 您好，我公司可生产 ...

Financial Performance - The company's operating revenue for 2022 was ¥830,041,323.93, a decrease of 5.45% compared to ¥877,929,541.89 in 2021[19] - The net profit attributable to shareholders for 2022 was ¥83,096,994.27, down 13.46% from ¥96,020,349.90 in the previous year[19] - The net profit after deducting non-recurring gains and losses was ¥65,668,739.12, reflecting a decline of 21.80% from ¥83,970,880.18 in 2021[19] - The net cash flow from operating activities decreased by 32.19% to ¥145,856,177.19 from ¥215,100,714.73 in 2021[19] - The basic earnings per share for 2022 was ¥0.2511, a decrease of 13.44% compared to ¥0.2901 in 2021[19] - Total assets at the end of 2022 were ¥2,966,606,675.95, an increase of 3.57% from ¥2,864,366,655.13 at the end of 2021[19] - The net assets attributable to shareholders increased by 3.51% to ¥2,154,978,185.80 from ¥2,081,809,739.53 in 2021[19] - The weighted average return on equity for 2022 was 3.92%, down from 4.72% in 2021[19] Revenue Breakdown - Pharmaceutical industry revenue increased by 1.94% to ¥677,932,465.36, accounting for 81.68% of total revenue[46] - Revenue from the cosmetics sector fell by 38.17% to ¥71,900,945.49, representing 8.66% of total revenue[46] - Sales of capsule products decreased by 6.84% to ¥383,662,265.23, while injection products saw a 22.49% increase to ¥264,937,275.59[46] - Sales revenue from health food products reached CNY 74,726,200, a slight decrease of 0.94% year-on-year[43] Research and Development - The company has established collaborations with well-known universities and research institutions to enhance its research and development capabilities[31] - The company developed and launched 5 new health food products during the reporting period, with a total of 16 products in the R&D pipeline[43] - The number of R&D personnel increased by 2.90% to 248 in 2022 from 241 in 2021[56] - The proportion of R&D personnel with a master's degree increased by 200% to 3 in 2022 from 1 in 2021[56] - Total R&D investment amounted to CNY 29,634,086.66 in 2022, a decrease of 21.15% from CNY 37,584,947.77 in 2021, representing 3.57% of operating revenue[57] Product Development and Market Strategy - The company has developed a complete ginseng industry chain, expanding from pharmaceutical production to cosmetics and health foods, with 11 dosage forms and 117 varieties of products[31] - The company aims to leverage modern technology while rooting itself in traditional culture to enhance its ginseng industry chain[31] - The company has developed 500+ cosmetic products, including skincare and makeup, leveraging its ginseng resources and technology[33] - The company aims to enhance its market share in the traditional Chinese medicine sector, focusing on optimizing product structure and increasing sales scale[74] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million yuan allocated for this purpose[97] Governance and Management - The company governance structure complies with relevant laws and regulations, ensuring effective operation and management[82] - The company has established a performance evaluation and incentive system linking management compensation to performance[83] - The company has a dedicated investor relations management system to ensure accurate and timely communication with investors[84] - The company has a clear asset ownership structure, ensuring no asset or fund occupation by the controlling shareholder[87] - The management team is expected to drive innovation and market expansion in the pharmaceutical sector[90] Environmental and Social Responsibility - The company emphasizes the importance of environmental compliance and may incur additional costs to meet stricter regulations[78] - The company has actively invested in environmental protection and energy-saving initiatives, adhering to relevant environmental regulations[132] - The company donated RMB 4.98 million worth of "Red Ginseng Paste Drink" to the Jilin Provincial Traditional Chinese Medicine Association and RMB 2.457 million worth of ginseng to epidemic prevention personnel in Jilin Province[132] Financial Health and Cash Flow - The company's retained earnings at the end of the reporting period amounted to RMB 846,881,870.12[119] - The net increase in cash and cash equivalents was CNY 123,568,861.36 in 2022, a significant improvement from a decrease of CNY 67,301,498.53 in 2021[59] - The company's total financial assets amounted to approximately CNY 127.35 million, with a decrease of 0.25% compared to the previous period[66] - The company's cash and cash equivalents rose to CNY 343,263,877.76 from CNY 219,695,016.40, showing a significant increase of approximately 56.23%[194] Shareholder Information - The company reported a total shareholding of 132,769,749 shares at the end of the reporting period, with a decrease of 554,900 shares[90] - The company distributed cash dividends of 0.30 RMB per 10 shares, totaling 9,928,548.00 RMB, based on a total share capital of 330,951,600 shares[115] - A cash dividend of RMB 0.50 per share (including tax) will be distributed to shareholders, totaling RMB 16,547,580.00, which represents 100% of the profit distribution[119] Risk Factors - The company faces risks including industry policy adjustments, rising production costs, and R&D risks, as noted in the management discussion[4] - The company faces risks related to industry policy adjustments, rising production costs, and potential talent shortages[76][78]